Moreover, we showed that SMYD3 stable knock-out or pharmacological inhibition drastically decreases CRC tumorigenicity in vivo and reduces the metastatic potential of CRC-SCs, indicating that SMYD3 is involved in primary tumor initiation and metastatic tumor dissemination. Here, SMYD3 is linked to colorectal carcinoma.